Pfizer (Essential Health / Injectable Opioids)(PFE)
HQ US75% share
pharmaceutical · input
Pneumococcal Conjugate Vaccine (PCV13/PCV20)
Polysaccharide-protein conjugate vaccines protecting against Streptococcus pneumoniae — the bacterium causing bacterial pneumonia, meningitis, sepsis, and otitis media. CDC schedules PCV for all US infants (4-dose series) and adults 65+. Pfizer Prevnar 13 held ~95% US market share for a decade; Prevnar 20 now expanding adult coverage. Second source: Merck Vaxneuvance (PCV15) entered market 2021.
0
Source countries
2
Companies
0
Goods affected
0
Claims on record
Who makes it
Supplier companies
2 companies produce pneumococcal conjugate vaccine (pcv13/pcv20).
Serum Institute of India
HQ IN22% share
World's largest vaccine manufacturer by dose volume — ~1.9–2.0 billion doses/year as of 2023, representing ~60% of global vaccine production. Produces routine childhood vaccines (polio, measles, DTP, BCG), COVID vaccines, and others for Gavi-eligible markets. Single-site concentration risk in Pune.